News

Apply now to attend the 74th Lindau meeting on chemistry

Published on | 4 months ago

Programmes MSCA

The European Commission is giving current and past Marie Skłodowska-Curie Actions fellows the opportunity to attend the next Lindau meeting on chemistry in summer 2025. The meeting of Nobel Laureates on chemistry will be held from 29 June to 4 July 2025 in Lindau, Germany. About 600 young scientists from all over the world will get the chance to spend an inspiring week with Nobel Laureates to exchange experiences and establish valuable contacts.

The European Commission is not offering travel or fee support for the event, merely the opportunity to attend thanks to a partnership with the Lindau Nobel Laureate Meetings organisers.

Applicants must ensure that they have the funding necessary to meet their own share of the costs of the event. This will amount to €1.250, plus travel costs, which can be covered with the budget of the fellow’s MSCA project or host organisation.

The call for applications is open to both current (you should have commenced your fellowship by 1 September 2024) and past MSCA fellows, including master, doctoral students and young postdoctoral scientists, working in the areas of chemistry or related fields. In addition to these criteria, the review panel of the Council for the Lindau Nobel Laureate meetings will select participants among the candidates using its own selection criteria.

The deadline to apply is 30 September 2024, 13h (CEST, Brussels time).

Find all the information on the selection criteria and how to apply in the MSCA news article

To find out more about the pre-selection of candidates by the FWO Research Foundation Flanders visit the FWO website. The application deadline is 18 September 2024.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1514 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.